Cleared Traditional

GRAHAM-FIELD SALINE ELECTROLYTE GEL (K944600) - FDA 510(k) Clearance

Class II Neurology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K944600 · Chester Labs, Inc. · Neurology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 1995
Decision
427d
Days
Class 2
Risk

K944600 is an FDA 510(k) clearance for the GRAHAM-FIELD SALINE ELECTROLYTE GEL. Classified as Media, Electroconductive (product code GYB), Class II - Special Controls.

Submitted by Chester Labs, Inc. (Erlanger, US). The FDA issued a Cleared decision on November 20, 1995 after a review of 427 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.1275 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Neurology submissions.

View all Chester Labs, Inc. devices

Submission Details

510(k) Number K944600 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 19, 1994
Decision Date November 20, 1995
Days to Decision 427 days
Submission Type Traditional
Review Panel Neurology (NE)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
279d slower than avg
Panel avg: 148d · This submission: 427d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code GYB Media, Electroconductive
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.1275
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.

Regulatory Peers - GYB Media, Electroconductive

All 13
Devices cleared under the same product code (GYB) and FDA review panel - the closest regulatory comparables to K944600.
Elefix V Paste for EEG & EMG
K191975 · Nihon Kohden Corporation · Feb 2020
SAC2 - Electrode Cream
K192606 · Spes Medica Srl · Jan 2020
Tech Dots - Adhesive and conductive gel
K190050 · Spes Medica Srl · Jul 2019
SKIN PURE
K862799 · Nihon Kohden America, Inc. · Nov 1986
ELEFIX ELECTRODE CREAM
K860210 · Nihon Kohden America, Inc. · Jul 1986